Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

NCT05979779 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Fatty Liver

Interventions

DRUG: HU6
OTHER: Placebo

Sponsor

Rivus Pharmaceuticals, Inc.